/MRSN
MRSN Stock - Mersana Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$28.94-0.55%
$0.16 (-0.55%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-41.3%upside
Target: $16.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRSN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$28.65 – $29.23
TARGET (TP)$17.00
STOP LOSS$26.62
RISK/REWARD1:-5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$40.88
52W Low$5.21
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $40.50M | $36.85M | $26.58M | $43,000 | $828,000 |
| Gross Profit | $40.50M | $36.85M | $26.58M | $43,000 | $-66,208,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -7996.1% |
| Operating Income | $-73,336,000 | $-170,957,000 | $-203,767,000 | $-168,858,000 | $-155,146,000 |
| Net Income | $-69,192,000 | $-171,670,000 | $-204,212,000 | $-170,060,000 | $-88,045,000 |
| Net Margin | -170.9% | -465.8% | -768.3% | -395488.4% | -10633.5% |
| EPS | $-14.12 | $-36.96 | $-54.51 | $-60.24 | $-35.80 |
Company Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
53%
Hold / Neutral
8
47%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
9 Bullish8 Neutral/Bearish
Price Targets
$7
Average Target
↓ 74.4% Downside
Now
$1
Low
$7
Average
$14
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 6th 2025 | William Blair | Initiation | Outperform | - |
| November 15th 2024 | Citigroup | Resumed | Buy | $5 |
| March 19th 2024 | JP Morgan | Upgrade | Neutral | $5 |
| February 29th 2024 | BTIG Research | Upgrade | Buy | $6 |
| February 29th 2024 | Guggenheim | Upgrade | Buy | $7 |
| February 29th 2024 | Wedbush | Upgrade | Outperform | $7← $2 |
| December 4th 2023 | Citigroup | Upgrade | Buy | $5← $1 |
| July 28th 2023 | Robert W. Baird | Downgrade | Neutral | $1← $7 |
| July 27th 2023 | JP Morgan | Downgrade | Underweight | - |
| July 27th 2023 | Citigroup | Downgrade | Neutral | - |
| July 27th 2023 | BTIG Research | Downgrade | Neutral | - |
| July 27th 2023 | Guggenheim | Downgrade | Neutral | - |
| July 27th 2023 | Truist | Downgrade | Hold | - |
| July 27th 2023 | Wedbush | Downgrade | Neutral | - |
| June 16th 2023 | JP Morgan | Downgrade | Neutral | $5← $11 |
Earnings History & Surprises
MRSNBeat Rate
33%
Last 18 quarters
Avg Surprise
-36.8%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-1.51
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.16vs$-0.20
Q2 24
+11.1%
$-0.16vs$-0.18
Q3 24
-11.1%
$-0.20vs$-0.18
Q4 24
+50.0%
$-0.09vs$-0.18
Q1 25
+31.3%
$-0.11vs$-0.16
Q2 25
+9.5%
$-4.75vs$-5.25
Q3 25
-8.8%
$-4.08vs$-3.75
Q4 25
-4.9%
$-1.51vs$-1.44
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-2.90 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.44 | $-1.51 | -4.9% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-3.75 | $-4.08 | -8.8% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-5.25 | $-4.75 | +9.5% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.18 | $-0.09 | +50.0% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.39 | $-0.47 | -20.5% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.41 | $-0.52 | -26.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.47 | $-0.44 | +6.4% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.09 | $-0.61 | -577.8% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.50 | $-0.55 | -10.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.31 | $-0.59 | -90.3% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.67 | $-0.68 | -1.5% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.58 | $-0.63 | -8.6% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.50 | $-0.59 | -18.0% | ✗ MISS |
Latest News
Guggenheim Downgrades Mersana Therapeutics to Neutral
➖ NeutralBenzinga•Nov 14, 2025, 02:15 PM
Mersana Therapeutics Q3 EPS $(1.51) Beats $(1.96) Estimate, Sales $11.009M Miss $14.203M Estimate
➖ NeutralBenzinga•Nov 14, 2025, 12:02 PM
Truist Securities Downgrades Mersana Therapeutics to Hold, Lowers Price Target to $30.75
📉 NegativeBenzinga•Nov 13, 2025, 06:00 PM
BTIG Downgrades Mersana Therapeutics to Neutral
📉 NegativeBenzinga•Nov 13, 2025, 05:45 PM
Mersana Therapeutics shares are trading higher after the company announced it will be acquired by Day One Biopharmaceuticals.
📈 PositiveBenzinga•Nov 13, 2025, 02:02 PM•Also:
Day One Biopharmaceuticals shares are trading lower after the company anounced it will acquire Mersana Therapeutics.
📉 NegativeBenzinga•Nov 13, 2025, 01:51 PM•Also:
Day One to buy Mersana Therapeutics for $25/share upfront
📈 PositiveSeeking Alpha•Nov 13, 2025, 11:27 AM
Day One Biopharmaceuticals Agrees To Acquire Mersana Therapeutics For $25 Per Share In Cash Plus One Non-tradable CVR Up To An Aggregate Of $30.25 Per CVR In Cash
📈 PositiveBenzinga•Nov 13, 2025, 11:05 AM•Also:
Mersana Misses Fiscal Q2 Revenue Target
📉 NegativeThe Motley Fool•Aug 13, 2025, 11:28 AM
Mersana Therapeutics to execute 1-for-25 reverse stock split
📉 NegativeSeeking Alpha•Jul 24, 2025, 12:39 PM
Frequently Asked Questions about MRSN
What is MRSN's current stock price?
Mersana Therapeutics, Inc. (MRSN) is currently trading at $28.94 per share. The stock has moved -0.55% today.
What is the analyst price target for MRSN?
The average analyst price target for MRSN is $17.00, based on 1 analyst.
What sector is Mersana Therapeutics, Inc. in?
Mersana Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MRSN's market cap?
Mersana Therapeutics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does MRSN pay dividends?
No, Mersana Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to MRSN for comparison